|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||26.48 - 26.62|
|52 Week Range||17.69 - 29.56|
|PE Ratio (TTM)||23.45|
|Forward Dividend & Yield||0.30 (1.12%)|
|1y Target Est||N/A|
A dearth of suitable targets may prompt acquisitive Swiss drug ingredients maker Lonza to expand its new drug product services business on its own, not via takeovers, Chief Financial Officer Rodolfo Savitzky told Reuters. Last year, Lonza poached Roche's biologics supply head, Hanns-Christian Mahler, to lead the unit whose "one-stop" services for pharmaceuticals companies include drug formulation development, analysis and quality control. Savitzky acknowledged Mahler's portfolio still lacks "fill-and-finish" activities, among the final steps in the drug manufacturing process for sophisticated biological medicines.
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
Categories: Yahoo FinanceGet free summary analysis Lonza Group AG reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Lonza Group AG – Sarepta Therapeutics, Inc. and Amgen Inc. (SRPT-US and AMGN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 2,359.22 million, ... Read more (Read more...)
Categories: Yahoo Finance Get free summary analysis Lonza Group AG reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of Lonza Group AG – Sarepta Therapeutics, Inc., Amgen Inc. and Merrimack Pharmaceuticals, Inc. (SRPT-US, AMGN-US and MACK-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)